OS Therapies rises after starting commercial production of cancer therapy

Fidia SpA

14/02/2025 14:57

** Shares of drug developer OS Therapies  OSTX.A  rise 31.1%
to $2.61 in morning trade  
    ** Co says it is starting commercial production of its
experimental therapy, OST-HER2 to treat a type of bone cancer
called osteosarcoma 
    ** OSTX says OST-HER2 has received "rare pediatric disease",
"fast-track" and "orphan drug" designations from the U.S. FDA
     ** Co says it anticipates submitting an application for
potential approval to the FDA for OST-HER2 in osteosarcoma in
2025  
    ** OSTX adds if the therapy is approved, it would be
eligible to receive a priority review voucher that it could then
sell
    ** Stock fell 20.7% since its debut 

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))